A nationwide survey of MYH9-related disease in Japan.

Yoko ShiraiKenichiro MiuraRiku HamadaKenji IshikuraShinji KunishimaMotoshi Hattori

Published in: Clinical and experimental nephrology (2023)

Our study demonstrated no beneficial effect of RAS inhibitors on kidney function in patients with MYH9-RD, indicating the need for further studies with more patients. All modalities of KRT are feasible options for MYH9-RD patients who progress to ESKD, with adequate attention to bleeding complications.

Keyphrases

hypertrophic cardiomyopathy
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
heart failure
patient reported outcomes